INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 448m ago
HOUSE PTR48m ago
SEC 13F48m ago
ROBINHOOD CHAIN48m ago
SEC FORM 4/Open-market purchaseVerified data

Stephenson Brian C bought FTH

Chief Financial Officer · Faeth Therapeutics, Inc. · Common Stock

Side
BUY
Value
$35K
Shares
1,583
Price
$22.4
Executed
Jun 22, 2026
Disclosed
Jun 24, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jun 22 executedJun 24, 2026 disclosed

FTH · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
46/ 100 · ELEVATED
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+13 / 25

    $35K reported value · 54.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · FTH

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    8
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Gift
    		G—
    100.0K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    12
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Gift
    		G—
    100.0K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SA
    Schayowitz AdamDirector
    FTHFaeth Therapeutics, Inc.
    Grant or award
    		A—
    25.0K sh
    		Oct 23, 2026Oct 27, 2026
    traded Oct 23, 2026
    		+4dSEC FORM 4

    Evidence

    9
    VH
    Vousden Karen HDirector
    FTHFaeth Therapeutics, Inc.
    Grant or award
    		A—
    25.0K sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    27
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$2,777
    100 sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    27
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$14K
    580 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$105K
    4,212 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    27
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$2,639
    100 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    27
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$35K
    1,358 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$92K
    3,400 sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$78K
    3,000 sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$73K
    2,891 sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    16
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Option exercise
    		M$52K
    45.3K sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    9
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Option exercise
    		M$9,527
    8,213 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    21
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Option exercise
    		M—
    45.3K sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    46
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$23K
    1,118 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    46
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$36K
    1,797 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    49
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$77K
    3,329 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$49K
    1,969 sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    30
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$11K
    425 sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001780030-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 22, 2026
    Published
    Jun 24, 2026
    Ingested by INSIDER
    Nov 5, 03:51 UTC
    Last re-read
    Nov 5, 03:51 UTC

    Extracted facts

    Filer
    Stephenson Brian C
    Role
    Chief Financial Officer
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    Faeth Therapeutics, Inc.
    Ticker
    FTH
    Shares
    1,583
    Price per share
    $22.4
    Value
    $35,459
    Execution date (reported)
    Jun 22, 2026
    Owned after transaction
    4,498 shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 1,583
    • Price: $22.4

    = $35,459

    What this establishes

    Stephenson Brian C filed this Form 4 reporting a open-market purchase of FTH on Jun 22, 2026. It became public on Jun 24, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Stephenson Brian Ccik:0001780030
    Issuer
    Faeth Therapeutics, Inc.cik:0001829802

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.